H3-DYNAMICS
16.1.2023 16:08:41 CET | Business Wire | Press release
H3 Dynamics and Hylium Industries have joined forces to boost the performance of zero emission hydrogen-electric flight, by combining the strengths of Hylium’s liquid hydrogen storage and liquification solutions, and H3 Dynamics’ distributed hydrogen-electric propulsion nacelles, ultra-light fuel cells, and new hydrogen drone refueling stations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230116005162/en/
Joint development for transatlantic crossing with ISAE-SUPAERO Toulouse, H3 Dynamics - using HYLIUM Liquid hydrogen storage (Photo: Business Wire)
Moving to liquid hydrogen represents a significant capability leap for small electric-powered unmanned systems. Cryogenic (liquid) hydrogen stores 3 times more energy as compressed gas in the same given volume. This means delivery drones will be able to fly further, mapping and ISR missions could be done on a much bigger scale.
To illustrate the jump in performance, the same 25kg hydrogen-electric propulsion UAV demonstrated by H3 Dynamics last July in France, will be able to fly over 900km with a single fill. With pressurized hydrogen, that range reduces to 400km, which is still 3 times more than a battery-powered equivalent.
“When combined, our global best-in-class solutions achieve the global performance limit for low-altitude electric powered flight” says Taras Wankewycz, CEO H3 Dynamics. “We are proud to be working with Hylium to move hydrogen-electric flight propulsion to the next level”
Now all the various forms of hydogen drones and UAVs powered by H3 Dynamics including hydrogen airships, multi-rotors, vertical take-off and landing (VTOL), have a way to further boost flight durations by another factor of 3 over pressurized hydrogen systems, or a factor of 10 compared to batteries.
H3 Dynamics also recently announced a first hydrogen production, and automated hydrogen refueling mobile station for hydrogen UAV operations. Named H2FIELD the mobile station produces hydrogen from water and delivers compressed hydrogen gas tanks to the operator with little human intervention and no required hydrogen expertise. H3 Dynamics and Hylium’s partnership will upgrade the station so that it can fill liquid hydrogen tanks.
Developed in South Korea, Hylium’s breakthrough technology provides one of the most advanced solutions and has already been proven in a number of applications. South Korea is also leading the development for LH2 standardisation. One local proposal was accepted as a draft standard by a global ISO committee.
Hylium and H3 Dynamics technologies are currently being integrated to attempt a 3,300km crossing of the South Atlantic, in a program led by ISAE SUPAERO Toulouse, one of the world’s leading aerospace engineering schools. H3 Dynamics’ team developed a special fuselage design that can store a small LH2 tank and manage the thermal behavior of all the propulsion sub-systems.
LH2 technology will also be a next step in H3 Dynamics’ hydrogen-electric propulsor nacelles roadmap. A first twin engine cargo drone powered by these self-contained nacelles took off in the sky of Paris during the summer 2022, using 2 compressed hydrogen tanks – one in each nacelle. The goal now will be to switch them out for liquid hydrogen tanks with a lighter construction and a higher fuel capacity.
About H3 Dynamics www.h3dynamics.com
H3 Dynamics is on a mission to decarbonize aviation with a unique technology solution around distributed hydrogen-electric propulsion, as well as hydrogen refueling and airport power solutions. The company has created a unique pathway to de-risk long term hydrogen aviation developments by starting commercially now with small, scalable solutions. H3 Dynamics employs 93 team members from its 3 regional headquarters in Toulouse, Austin and Singapore. It is a member of the Alliance for Zero Emission Aviation under the European Commission, Sustainable Aero Lab, the Lufthansa Cleantech Hub, the Paris Advanced Air Mobility Alliance, and Aerospace Valley in Toulouse.
About Hylium Industries: http://hylium-industries.com/
HYLIUM INDUSTRIES, INC. was established in 2014 as a Korea Institute of Science and Technology (KIST) venture company. Since then Hylium have been developing the Korea’s first cryogenic liquid hydrogen manufacturing and storage technologies with R&D support from the Korean Government.
Hylium has developed various technologies related to the hydrogen liquefaction system and owns over 20 patents and intellectual property rights, with more patents pending. In 2015 Hylium Industries’ technologies were acknowledged by the Cryogenic Engineering Conference with a Russel B. Scott Memorial Award for the Best Application in Small-Capacity Hydrogen Liquefaction Technology.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230116005162/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
DEWA Organises Second Agentic AI Retreat at Al Shera’a, World’s Tallest, Largest and Smartest Net‑Positive Government Building12.6.2026 17:08:00 CEST | Press release
HE Saeed Mohammed Al Tayer, MD & CEO of Dubai Electricity and Water Authority (DEWA),has emphasised that DEWA deploys the latest Agentic AI technologies, in line with the vision to enhance its leading role and reinforce Dubai’s position as the city of the future. He made these remarks during the Agentic AI Executive Retreat DEWA organised at Al Shera’a, its new headquarters, which is the world’s tallest, largest and smartest net-positive government building. The event was attended by the executive leadership team and key stakeholders in digital transformation and artificial intelligence (AI), as well as representatives from SAP and McKinsey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612633834/en/ DEWA organises second Agentic AI Retreat at Al Shera’a, world’s tallest, largest and smartest net positive government building (Photo: AETOSWire) In his speech, Al Tayer said that DEWA is guided by directives from the wise l
BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 202612.6.2026 12:00:00 CEST | Press release
Tacabrutideg (BGB-16673, BTK degrader) showed durable responses in heavily pretreated R/R CLL and BTK inhibitor–naïve patients, signaling potential for earlier lines of treatmentBRUKINSA plus sonrotoclax (ZS) delivered deep, durable responses and high uMRD rates across TN CLL and R/R MCL and CLL, reinforcing its potential as an all-oral, fixed-duration treatment BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association (EHA) Congress in Stockholm. Updated results from tacabrutideg (BGB-16673), a potential best-in-class Bruton’s tyrosine kinase (BTK) degrader, demonstrated durable responses in pretreated relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), with early activity also seen in BTK inhibitor–naïve patients. These data are complemented by results from the all-oral combination of BRUKINSA® (zanubru
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
